| __timestamp | Bristol-Myers Squibb Company | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 7751000 |
| Thursday, January 1, 2015 | 5001000000 | 10251000 |
| Friday, January 1, 2016 | 5002000000 | 9575000 |
| Sunday, January 1, 2017 | 4849000000 | 10912000 |
| Monday, January 1, 2018 | 4551000000 | 11049000 |
| Tuesday, January 1, 2019 | 4871000000 | 11646000 |
| Wednesday, January 1, 2020 | 7661000000 | 13265000 |
| Friday, January 1, 2021 | 7690000000 | 25805000 |
| Saturday, January 1, 2022 | 7814000000 | 35182000 |
| Sunday, January 1, 2023 | 7772000000 | 94999000 |
| Monday, January 1, 2024 | 8414000000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Bristol-Myers Squibb Company, a titan in the field, has consistently demonstrated robust financial management. From 2014 to 2023, their Selling, General, and Administrative (SG&A) expenses have shown a steady increase, peaking in 2022 with a 37% rise from 2014. This reflects their strategic investments in marketing and administration to maintain their market dominance.
In contrast, Viridian Therapeutics, Inc., a smaller player, has seen a dramatic surge in SG&A expenses, particularly in 2023, where expenses skyrocketed by over 1,100% compared to 2014. This indicates a significant scaling of operations, likely in pursuit of growth and market penetration. The juxtaposition of these two companies offers a fascinating insight into how different scales of operations impact financial strategies in the pharmaceutical sector.
Who Optimizes SG&A Costs Better? Sanofi or Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or GSK plc: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company vs Summit Therapeutics Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs MannKind Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Geron Corporation
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.
Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Vericel Corporation and Viridian Therapeutics, Inc.
Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Ligand Pharmaceuticals Incorporated and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared